Copanlisib

Generic Name
Copanlisib
Brand Names
Aliqopa
Drug Type
Small Molecule
Chemical Formula
C23H28N8O4
CAS Number
1032568-63-0
Unique Ingredient Identifier
WI6V529FZ9
Background

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was gr...

Indication

Copanlisib is indicated for the treatment of adults with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. This indication was granted under accelerated approval; thus, continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Associated Conditions
Relapsed Follicular Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

First Posted Date
2024-05-06
Last Posted Date
2024-11-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
35
Registration Number
NCT06400238
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

First Posted Date
2024-04-11
Last Posted Date
2024-10-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
35
Registration Number
NCT06360588
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

First Posted Date
2024-01-23
Last Posted Date
2024-10-31
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
37
Registration Number
NCT06218667
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

Phase 1
Not yet recruiting
Conditions
Advanced Urothelial Carcinoma
Interventions
Drug: copanlisib
Drug: Avelumab
First Posted Date
2023-01-18
Last Posted Date
2024-08-07
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
29
Registration Number
NCT05687721
Locations
🇺🇸

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Phase 2
Active, not recruiting
Conditions
Follicular Lymphoma
Interventions
Drug: Copanlisib
Drug: Obinutuzumab
First Posted Date
2022-05-24
Last Posted Date
2024-03-12
Lead Sponsor
Ludwig-Maximilians - University of Munich
Target Recruit Count
98
Registration Number
NCT05387616
Locations
🇩🇪

Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, Germany

🇩🇪

Universitätsklinikum Jena, Jena, Germany

🇩🇪

Charité Campus Benjamin Franklin, Berlin, Germany

and more 37 locations

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase 2
Active, not recruiting
Conditions
Ovarian Cancer
Endometrial Cancer
Interventions
Drug: Copanlisib
Drug: fulvestrant
First Posted Date
2021-10-18
Last Posted Date
2024-12-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
7
Registration Number
NCT05082025
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

First Posted Date
2021-08-18
Last Posted Date
2022-05-27
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT05010096

Lung Cancer With Copanlisib and Durvalumab

Phase 1
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Durvalumab
Drug: Copanlisib
First Posted Date
2021-05-20
Last Posted Date
2024-02-13
Lead Sponsor
Zhonglin Hao
Target Recruit Count
11
Registration Number
NCT04895579
Locations
🇺🇸

Markey Cancer Center, Lexington, Kentucky, United States

Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Early Phase 1
Terminated
Conditions
Leukemia, Acute Lymphocytic
Interventions
Drug: Copanlisib
First Posted Date
2021-03-17
Last Posted Date
2023-12-21
Lead Sponsor
Dorothy Sipkins, MD, PhD
Target Recruit Count
3
Registration Number
NCT04803123
Locations
🇺🇸

Duke Cancer Center, Durham, North Carolina, United States

Study of Copanlisib and Ketogenic Diet

Phase 2
Active, not recruiting
Conditions
Follicular Lymphoma
Endometrial Cancer
Interventions
Drug: Copanlisib
Other: Ketogenic Diet
First Posted Date
2021-02-11
Last Posted Date
2023-06-08
Lead Sponsor
Columbia University
Target Recruit Count
1
Registration Number
NCT04750941
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy